TAC Versus TCX as Adjuvant Treatment for High-risk Her2-Negative Breast Cancer
NCT01354522
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
204
Enrollment
OTHER
Sponsor class
Conditions
Breast Cancer
Interventions
DRUG:
Docetaxel, Doxorubicin, Cyclophosphamide
DRUG:
Docetaxel, Cyclophosphamide, Capecitabine
Sponsor
Peking Union Medical College Hospital